Fabry disease: A systemic disease;Maladie de Fabry: Maladie systémique

Medecine Therapeutique - Cardio

Volumn 2, Issue 3, 2006, Pages 355-365

  Lidove, Olivier ^a,b   Iung, Bernard ^a   Brochet, Eric ^a   Himbert, Dominique ^a   Deliu, Floriana ^a   Laissy, Jean Pierre ^a   Andrès, Emmanuel ^c   Papo, Thomas ^a,b  

^a BICHAT HOSPITAL   (France)

^b BEAUJON HOSPITAL   (France)

^c HÔPITAL CIVIL   (France)

Author keywords

Enzyme replacement therapy; Fabry disease; Hypertrophic cardiomyopathy; Pedigree

Indexed keywords

ECHOGRAPHY; ELECTROCARDIOGRAPHY; ENZYME REPLACEMENT; FABRY DISEASE; HISTOPATHOLOGY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PEDIGREE; PHENOTYPE; REVIEW; SYSTEMIC DISEASE; X CHROMOSOME LINKED DISORDER;

EID: 33746891524     PISSN: 17748747     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol 1996; 40: 8-17.
2. Bass JL, Shrivastava S, Grabowski GA, Desnick RJ, Moller JH. The M-mode echocardiogram in Fabry's disease. Am Heart J 1980; 100: 807-12.
3. Tanaka H, Adachi K, Yamashita Y, Toshima H, Koga Y. Four cases of Fabry's disease mimicking hypertrophic cardiomyopathy. J Cardiol 1988; 18: 705-18.
4. Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000; 139: 1101-8.
5. Nishimura RA, Holmes Jr. DR. Hypertrophic Obstructive Cardiomyopathy. N Engl J Med 2004; 350: 1320-7.
6. Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004; 110: 1047-53.
7. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995; 333: 288-93.
8. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352: 362-72.
9. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105: 1407-11.
10. Weidemann F, Breunig F, Beer M, et al. The variation of morphological functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005; 26: 1221-7.
11. Moon JCC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Eur Heart J 2003; 24: 2151-5.
12. Lidove O, Klein I, Lelievre JD, et al. Imaging features of Fabry disease. AJR Am J Roentgenol 2006; 186: 1184-91.
13. Kampmann C, Baehner FA, Whybra C, et al. The right ventricle in Fabry disease. Acta Paediatr Suppl 2005; 94: 15-8.
14. Cohen IS, Fluri-Lundeen J, Wharton TP. Two dimensional echocardiographic similarity of Fabry's disease to cardiac amyloidosis: a function of ultrastructural analogy? J Clin Ultrasound 1983; 11: 437-41.
15. Elleder M, Bradova V, Smid F, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease: report on a case simulating non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990; 417: 449-55.
16. Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and severity in Fabry's disease. J Am Coll Cardiol 1986; 7: 1157-61.
17. Sakuraba H, Yanagawa Y, Igarashi T, et al. Cardiovascular manifestations in Fabry's disease. Clin Genet 1986; 29: 276-83.
18. Ries M, Gupta S, Moore DF, et al. Pediatric Fabry disease. Paediatrics 2005; 115: e344-e355.
19. Ries M, Ramaswami U, Parini R, et al. The early clinical phenotype of Fabry disease: a study of 35 european children and adolescents. Eur J Pediatr 2003; 162: 767-72.
20. Elhadad S, Melet V, Domniez T, Cosson S, Chollet D, Vedel J. Bloc auriculo-ventriculaire complet révélateur de maladie de Fabry. Arch Mal Coeur Vaiss 1997; 90: 393-7.
21. Schiffmann R, Kopp JB, Austin 3rd HA, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743-9.
22. Shah JS, Hughes DA, Sachdev B, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005; 96: 842-6.
23. Mac Dermot KD, Holmes H, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38: 769-75.
24. Elliott PM, Kindler H, Shah JS, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 2006; 92: 357-60.
25. Fisher EA, Desnick RJ, Gordon RE, Eng CM, Griepp R, Goldman ME. Fabry disease: an unusual cause of severe coronary disease in a young man. Ann Intern Med 1992; 117: 221-3.
26. Boutouyrie P, Laurent S, Laloux B, Lidove O, Grunfeld JP, Germain DP. Non-invasive evaluation of arterial involvement in patients affected with Fabry disease. J Med Genet 2001; 38: 629-31.
27. Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease. Medicine 2005; 84: 261-8.
28. Deegan P, Baehner AF, Barba-Romero MA, Hughes D, Kampmann C, Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006; 43: 347-52.
29. Cantor WJ, Daly P, Iwanochko M, Clarke JTR, Cusimano RJ, Butany J. Cardiac transplantation for Fabry's disease. Can J Cardiol 1998; 14: 81-4.
30. Young E, Mills K, Morris B, et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 2005; 94: 51-4.
31. Linhart A, Magage S, Palecek T, Bultas J. Cardiac involvement in Fabry disease. Acta Paediatr 2002; 91: 15-20.
32. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16.
33. Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003; 108: 1299-301.
34. Spinelli L, Pisani A, Sabbatini M, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 2004; 66: 158-65.
35. Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of aphase IIIB study. J Inherit Metab Dis 2003; 26: 617-27.
36. Waldek S. PR interval and the response to enzyme-replacement therapy in Fabry's disease. N Engl J Med 2003; 348: 1186-7.
37. Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001; 345: 25-32.
38. Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75: 65-74.
39. Schiffmann R, Ries M, Timmons M, et al. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006; 21: 345-54.
40. Moore DF, Scott LT, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001; 104: 1506-12.
41. Gold KF, Pastures GM, Botteman MF, et al. Quality of life of patients with Fabry disease. Qual Life Res 2002; 11: 317-27.
42. Shah JS, Lee P, Hughes D, et al. The natural history of left ventricular systolic function in Anderson-Fabry disease. Heart 2005; 91: 533-4.